Ikena Oncology is a targeted oncology company developing medicines tailored to biomarker-defined patient groups. Co.'s programs are across the Hippo pathway, RAS pathway, and key immune signals in the tumor-microenvironment, with approaches to targeting both cancer driving targets and mechanisms of resistance to targeted therapies. Co.'s primary targeted oncology product candidate, IK-930, is an oral small molecule inhibitor of the transcriptional enhanced associate domain transcription factor in the Hippo signaling pathway. Co.'s clinical-stage programs also include product candidates in development to target immune signaling in the tumor microenvironment.